NO20021197L - Fremgangsmåte til behandling av stoffskiftesykdommer, spesielt diabetes, eller en sykdom eller tilstand forbundet meddiabetes - Google Patents

Fremgangsmåte til behandling av stoffskiftesykdommer, spesielt diabetes, eller en sykdom eller tilstand forbundet meddiabetes

Info

Publication number: NO20021197L
Authority: NO; Norway
Prior art keywords: diabetes; disease; condition associated; metabolic disorders; treating metabolic
Prior art date: 1999-09-17

Application number

NO20021197A

Other languages

English (en)

Other versions

NO20021197D0 (no

Inventor

Marjorie Regan Gatlin

Richard Owen Mannion

Anees Abdulquadar Karnachi

Malcolm Allison

Michele Pongowski

Christiane Guitard

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-17

Filing date

2002-03-11

Publication date

2002-05-16

2000-08-26 Priority claimed from GB0021055A external-priority patent/GB0021055D0/en

2002-03-11 Application filed by Novartis Ag filed Critical Novartis Ag

2002-03-11 Publication of NO20021197D0 publication Critical patent/NO20021197D0/no

2002-05-16 Publication of NO20021197L publication Critical patent/NO20021197L/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Child & Adolescent Psychology (AREA)
Immunology (AREA)
Emergency Medicine (AREA)
Gynecology & Obstetrics (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20021197A 1999-09-17 2002-03-11 Fremgangsmåte til behandling av stoffskiftesykdommer, spesielt diabetes, eller en sykdom eller tilstand forbundet meddiabetes NO20021197L (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US39836499A	1999-09-17	1999-09-17
US54548000A	2000-04-07	2000-04-07
GB0021055A GB0021055D0 (en)	2000-08-26	2000-08-26	Method of treating metabolic disorders,espicially diabetes,or a disease or condition associated with diabetes
PCT/EP2000/009074 WO2001021159A2 (en)	1999-09-17	2000-09-15	Pharmaceutical composition of nateglinide and another antidiabetcagent

Publications (2)

Publication Number	Publication Date
NO20021197D0 NO20021197D0 (no)	2002-03-11
NO20021197L true NO20021197L (no)	2002-05-16

Family

ID=27255861

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20021197A NO20021197L (no)	1999-09-17	2002-03-11	Fremgangsmåte til behandling av stoffskiftesykdommer, spesielt diabetes, eller en sykdom eller tilstand forbundet meddiabetes

Country Status (25)

Country	Link
EP (2)	EP1212077A2 (no)
JP (2)	JP2003509457A (no)
KR (2)	KR100506428B1 (no)
CN (1)	CN1309380C (no)
AR (3)	AR028299A1 (no)
AU (1)	AU7904400A (no)
BE (1)	BE1013726A5 (no)
BR (1)	BR0014525A (no)
CA (1)	CA2381992C (no)
CO (1)	CO5200844A1 (no)
CZ (1)	CZ20011723A3 (no)
FI (1)	FI20010683L (no)
FR (1)	FR2798592B1 (no)
HK (1)	HK1046101A1 (no)
HU (1)	HUP0400932A3 (no)
IL (1)	IL148168A0 (no)
MY (2)	MY143051A (no)
NO (1)	NO20021197L (no)
NZ (2)	NZ517280A (no)
PE (1)	PE20010739A1 (no)
PL (1)	PL354168A1 (no)
SG (1)	SG127714A1 (no)
SK (1)	SK3602002A3 (no)
TW (2)	TWI278311B (no)
WO (1)	WO2001021159A2 (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6586438B2 (en)	1999-11-03	2003-07-01	Bristol-Myers Squibb Co.	Antidiabetic formulation and method
AU2226901A (en)	1999-12-28	2001-07-09	Ajinomoto Co., Inc.	Oral preparations for diabetes
EP1283054A4 (en) *	2000-03-17	2006-04-12	Ajinomoto Kk	MEDICAMENTS FOR TREATING THE COMPLICATIONS OF DIABETES AND NEUROPATHIES AND USE THEREOF
FR2809310B1 (fr) *	2000-05-26	2004-02-13	Centre Nat Rech Scient	Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
FR2816840B1 (fr)	2000-11-17	2004-04-09	Flamel Tech Sa	Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
CA2369967A1 (en) *	2001-02-12	2002-08-12	Joseph Anthony Cornicelli	Methods of treating nuclear factor-kappa b mediated diseases and disorders
CA2439063A1 (en) *	2001-03-12	2002-09-19	Novartis Ag	Combination of nateglinide or repaglinide with at least one further antidiabetic compound
FR2825023B1 (fr) *	2001-05-23	2005-04-15	Flamel Tech Sa	Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
FR2826278B1 (fr) *	2001-06-20	2005-03-25	Lipha	Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant
ES2275889T3 (es) *	2001-06-20	2007-06-16	Merck Sante	Utilizacion de agentes antidiabeticos para fabricar un medicamento que tiene un efecto cicatrizante.
EP1483232A1 (en) *	2002-03-11	2004-12-08	Novartis AG	Salts of nateglinide
WO2003084518A2 (fr)	2002-04-09	2003-10-16	Flamel Technologies	Suspension orale de microcapsules de principes actifs
DE60335810D1 (de) *	2002-05-28	2011-03-03	Ajinomoto Kk	Medizinische zusammensetzungen zur hemmung der expression von atp-citrat-lyase und ihre verwendung
US6830759B2 (en)	2002-06-28	2004-12-14	Ajinomoto Co., Inc.	Antidiabetic preparation for oral administration
US6861553B2 (en)	2002-07-03	2005-03-01	Teva Pharmaceuticals Industries Ltd.	Process for preparing nateglinide and intermediates thereof
US7148376B2 (en)	2002-07-18	2006-12-12	Teva Pharmaceutical Industries Ltd.	Polymorphic forms of nateglinide
US7534913B2 (en)	2002-07-18	2009-05-19	Teva Pharmaceutica Industries Ltd.	Crystalline form of nateglinide
US7358390B2 (en)	2002-07-18	2008-04-15	Teva Pharmaceutical Industries Ltd.	Polymorphic forms of nateglinide
US7420084B2 (en)	2002-07-18	2008-09-02	Teva Pharmaceutical Industries Ltd.	Polymorphic forms of nateglinide
UA80991C2 (en)	2002-10-07	2007-11-26		Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
WO2005013964A1 (ja)	2003-08-08	2005-02-17	Ajinomoto Co., Inc.	ナテグリニド含有製剤
KR20120064735A (ko) *	2004-04-01	2012-06-19	아지노모토 가부시키가이샤	나테글리니드 함유 제제
PL2489659T3 (pl)	2004-06-24	2018-06-29	Vertex Pharma	Modulatory transporterów posiadających kasetę wiążącą atp
JP5551852B2 (ja) *	2004-08-10	2014-07-16	味の素株式会社	苦味の低減したナテグリニド含有製剤
PT1993360T (pt)	2005-12-28	2017-05-25	Vertex Pharma	Formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-di-hidro-4-oxoquinolina-3-carboxamida
WO2007111933A2 (en) *	2006-03-22	2007-10-04	Intranasal Therapeutics , Inc.	Pharmaceutical compositions comprising a hypoglycemic agent and methods of using same
US12458635B2 (en)	2008-08-13	2025-11-04	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
US20100172916A1 (en) *	2008-11-10	2010-07-08	Auspex Pharmaceuticals, Inc.	Substituted hydroxyphenylamine compounds
WO2010060041A2 (en) *	2008-11-21	2010-05-27	Auspex Pharmaceuticals, Inc.	Phenylalanine amide inhibitors of atp-sensitive potassium channels
EP3330255B1 (en)	2009-03-20	2020-12-09	Vertex Pharmaceuticals Incorporated	Process for making modulators of cystic fibrosis transmembrane conductance regulator
KR101035574B1 (ko) *	2009-04-09	2011-05-23	대한민국	제 2형 당뇨병 치료효과를 판정하는 방법
TWI631963B (zh) *	2011-01-05	2018-08-11	雷西肯製藥股份有限公司	包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
AU2012204162B2 (en)	2011-01-07	2017-04-20	Anji Pharmaceuticals Inc.	Chemosensory receptor ligand-based therapies
US9211263B2 (en)	2012-01-06	2015-12-15	Elcelyx Therapeutics, Inc.	Compositions and methods of treating metabolic disorders
US11974971B2 (en)	2011-01-07	2024-05-07	Anji Pharmaceuticals Inc.	Compositions and methods for treating metabolic disorders
US8796338B2 (en)	2011-01-07	2014-08-05	Elcelyx Therapeutics, Inc	Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en)	2011-01-07	2017-02-21	Elcelyx Therapeutics, Inc.	Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US9480663B2 (en)	2011-01-07	2016-11-01	Elcelyx Therapeutics, Inc.	Biguanide compositions and methods of treating metabolic disorders
US11759441B2 (en)	2011-01-07	2023-09-19	Anji Pharmaceuticals Inc.	Biguanide compositions and methods of treating metabolic disorders
WO2013066277A1 (en) *	2011-11-03	2013-05-10	Mahmut Bilgic	Synergic compositions
WO2013077820A1 (en) *	2011-11-23	2013-05-30	Mahmut Bilgic	Treatment package composed of dosage forms comprising nateglinide -metformin hydrochloride
KR102035879B1 (ko)	2012-01-06	2019-10-23	엘셀릭스 테라퓨틱스 인코포레이티드	바이구아나이드 조성물 및 대사 장애를 치료하는 방법
KR102231554B1 (ko)	2012-01-06	2021-03-23	앤지 파마 유에스 엘엘씨	대사 장애를 치료하는 조성물 및 방법
IL311180A (en)	2012-02-27	2024-04-01	Vertex Pharma	Pharmaceutical preparations containing a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and uses thereof
CN107250113B (zh)	2014-10-07	2019-03-29	弗特克斯药品有限公司	囊性纤维化跨膜传导调节蛋白的调节剂的共晶
CN105646332B (zh) *	2014-11-09	2018-05-25	复旦大学	氨基甲基哌啶类衍生物及其制备方法和药物用途
CN114099520A (zh) *	2021-12-31	2022-03-01	中国药科大学	格列喹酮用于制备治疗溃疡性结肠炎的药物的用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3561444A (en)	1968-05-22	1971-02-09	Bio Logics Inc	Ultrasonic drug nebulizer
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3630200A (en)	1969-06-09	1971-12-28	Alza Corp	Ocular insert
US3703173A (en)	1970-12-31	1972-11-21	Ted A Dixon	Nebulizer and tent assembly
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
JPS5522636A (en)	1978-08-04	1980-02-18	Takeda Chem Ind Ltd	Thiazoliding derivative
JPS55129221A (en) *	1979-03-29	1980-10-06	Kaken Pharmaceut Co Ltd	Preparation of oral preparation containing hardly soluble medicine
JPS56110612A (en) *	1980-02-08	1981-09-01	Yamanouchi Pharmaceut Co Ltd	Readily disintegrable and absorbable compression molded article of slightly soluble drug
JPS55129220A (en) *	1980-02-08	1980-10-06	Yamanouchi Pharmaceut Co Ltd	Composition for solid preparation containing hardly soluble medicinal component having rapid action and high bioavailability
JPS6051189A (ja)	1983-08-30	1985-03-22	Sankyo Co Ltd	チアゾリジン誘導体およびその製造法
US5216167A (en)	1983-12-30	1993-06-01	Dr. Karl Thomae Gmbh	Phenylacetic acid benzylamides
US4624251A (en)	1984-09-13	1986-11-25	Riker Laboratories, Inc.	Apparatus for administering a nebulized substance
US4635627A (en)	1984-09-13	1987-01-13	Riker Laboratories, Inc.	Apparatus and method
AR240698A1 (es)	1985-01-19	1990-09-28	Takeda Chemical Industries Ltd	Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
JPS6354321A (ja) *	1985-03-27	1988-03-08	Ajinomoto Co Inc	血糖降下剤
HU210339B (en)	1985-05-21	1995-03-28	Pfizer	Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect
US4806359A (en) *	1987-04-22	1989-02-21	Mcneilab, Inc.	Iburprofen sustained release matrix and process
EP0306228B1 (en)	1987-09-04	1999-11-17	Beecham Group Plc	Substituted thiazolidinedione derivatives
WO1989008651A1 (en)	1988-03-08	1989-09-21	Pfizer Inc.	Hypoglycemic thiazolidinedione derivatives
US4997948A (en)	1989-10-27	1991-03-05	American Home Products	5-[(1- and 2-naphthalenyl) sulfonyl]-2,4-thiazolidinediones and derivatives thereof
EP0526171B1 (en)	1991-07-30	1997-03-05	Ajinomoto Co., Inc.	Crystals of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine and methods for preparing them
US5463116A (en) *	1991-07-30	1995-10-31	Ajinomoto Co., Inc.	Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
JP2845743B2 (ja)	1992-12-28	1999-01-13	三菱化学株式会社	新規なナフタレン誘導体
JPH0776516A (ja) *	1993-09-06	1995-03-20	Toyobo Co Ltd	難溶性薬物含有製剤の製造方法
JPH07126154A (ja) *	1993-10-29	1995-05-16	Terumo Corp	難水溶性医薬品含有医薬製剤
US5488510A (en)	1994-07-26	1996-01-30	Lemay; Edward J.	Enhanced depth perception viewing device for television
TWI238064B (en) *	1995-06-20	2005-08-21	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
JP4010377B2 (ja)	1996-09-06	2007-11-21	杏林製薬株式会社	Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
DE19637082A1 (de) *	1996-09-12	1998-03-19	Boehringer Mannheim Gmbh	Schnellzerfallende Pellets
EP2277517A1 (en) *	1996-11-15	2011-01-26	Ajinomoto Co., Inc.	Nateglinide tablet composition
EP1011673B1 (en) *	1997-06-13	2001-05-16	Novo Nordisk A/S	Novel niddm regimen

2000
- 2000-09-14 CO CO00069666A patent/CO5200844A1/es not_active Application Discontinuation
- 2000-09-14 AR ARP000104821A patent/AR028299A1/es not_active Application Discontinuation
- 2000-09-15 NZ NZ517280A patent/NZ517280A/en not_active IP Right Cessation
- 2000-09-15 WO PCT/EP2000/009074 patent/WO2001021159A2/en not_active Ceased
- 2000-09-15 BE BE2000/0585A patent/BE1013726A5/fr not_active IP Right Cessation
- 2000-09-15 IL IL14816800A patent/IL148168A0/xx unknown
- 2000-09-15 KR KR10-2002-7003551A patent/KR100506428B1/ko not_active Expired - Fee Related
- 2000-09-15 SG SG200401291A patent/SG127714A1/en unknown
- 2000-09-15 FR FR0011782A patent/FR2798592B1/fr not_active Expired - Fee Related
- 2000-09-15 HK HK02107767.4A patent/HK1046101A1/zh unknown
- 2000-09-15 EP EP00969260A patent/EP1212077A2/en not_active Ceased
- 2000-09-15 TW TW089118960A patent/TWI278311B/zh not_active IP Right Cessation
- 2000-09-15 CN CNB008019762A patent/CN1309380C/zh not_active Expired - Lifetime
- 2000-09-15 HU HU0400932A patent/HUP0400932A3/hu unknown
- 2000-09-15 MY MYPI20050152A patent/MY143051A/en unknown
- 2000-09-15 TW TW092125226A patent/TWI278312B/zh not_active IP Right Cessation
- 2000-09-15 JP JP2001524585A patent/JP2003509457A/ja not_active Withdrawn
- 2000-09-15 BR BR0014525-4A patent/BR0014525A/pt not_active IP Right Cessation
- 2000-09-15 AU AU79044/00A patent/AU7904400A/en not_active Abandoned
- 2000-09-15 NZ NZ528738A patent/NZ528738A/en not_active IP Right Cessation
- 2000-09-15 KR KR1020047010952A patent/KR100544244B1/ko not_active Expired - Fee Related
- 2000-09-15 MY MYPI20004314A patent/MY131810A/en unknown
- 2000-09-15 PE PE2000000955A patent/PE20010739A1/es not_active Application Discontinuation
- 2000-09-15 EP EP08167253A patent/EP2011507A2/en not_active Withdrawn
- 2000-09-15 CA CA2381992A patent/CA2381992C/en not_active Expired - Fee Related
- 2000-09-15 PL PL00354168A patent/PL354168A1/xx not_active Application Discontinuation
- 2000-09-15 SK SK360-2002A patent/SK3602002A3/sk unknown
- 2000-09-15 CZ CZ20011723A patent/CZ20011723A3/cs unknown
- 2000-09-15 FI FI20010683A patent/FI20010683L/fi not_active Application Discontinuation
2001
- 2001-02-05 AR ARP010100516A patent/AR028504A2/es unknown
2002
- 2002-03-11 NO NO20021197A patent/NO20021197L/no unknown
2006
- 2006-09-06 JP JP2006241423A patent/JP2006335767A/ja active Pending
2009
- 2009-07-28 AR ARP090102868A patent/AR072329A2/es unknown

Also Published As

Publication number	Publication date
NZ528738A (en)	2005-05-27
HK1046101A1 (zh)	2002-12-27
FR2798592A1 (fr)	2001-03-23
BR0014525A (pt)	2002-06-11
NZ517280A (en)	2004-02-27
EP2011507A2 (en)	2009-01-07
CA2381992A1 (en)	2001-03-29
AU7904400A (en)	2001-04-24
CA2381992C (en)	2011-03-29
FI20010683A7 (fi)	2001-04-02
KR100506428B1 (ko)	2005-08-05
NO20021197D0 (no)	2002-03-11
TWI278311B (en)	2007-04-11
HUP0400932A3 (en)	2007-11-28
PL354168A1 (pl)	2003-12-29
MY131810A (en)	2007-09-28
HUP0400932A2 (hu)	2004-07-28
CO5200844A1 (es)	2002-09-27
MY143051A (en)	2011-02-28
SG127714A1 (en)	2006-12-29
TWI278312B (en)	2007-04-11
IL148168A0 (en)	2002-09-12
AR072329A2 (es)	2010-08-25
EP1212077A2 (en)	2002-06-12
CN1635874A (zh)	2005-07-06
TW200401631A (en)	2004-02-01
JP2003509457A (ja)	2003-03-11
KR100544244B1 (ko)	2006-01-23
FR2798592B1 (fr)	2007-04-20
CN1309380C (zh)	2007-04-11
CZ20011723A3 (cs)	2001-08-15
BE1013726A5 (fr)	2002-07-02
FI20010683L (fi)	2001-05-15
KR20020038758A (ko)	2002-05-23
PE20010739A1 (es)	2001-07-13
WO2001021159A3 (en)	2001-12-27
KR20040075935A (ko)	2004-08-30
WO2001021159A2 (en)	2001-03-29
SK3602002A3 (en)	2002-07-02
AR028299A1 (es)	2003-05-07
JP2006335767A (ja)	2006-12-14
AR028504A2 (es)	2003-05-14

Publication	Publication Date	Title
NO20021197D0 (no)	2002-03-11	Fremgangsmåte til behandling av stoffskiftesykdommer, spesielt diabetes, eller en sykdom eller tilstand forbundet meddiabetes
BR9712808B1 (pt)	2009-05-05	indol-3-glioxilamidas n-substituìdas, bem como aplicação, medicamento e processo para a preparação das mesmas.
AU2003233437A8 (en)	2003-10-13	System for the diagnosis and monitoring of coronary artery disease, acute coronary syndromes, cardiomyopathy and other cardiac conditions
TR199801587A3 (tr)	1999-03-22	Insülin öncü moleküllerinin elde edilmesine yönelik yöntem.
BR9804504B1 (pt)	2009-01-13	isoquinolina-3-carboxamidas substituÍdas, processo para a preparaÇço das mesmas e medicamento.
NO20053041D0 (no)	2005-06-21	Behandling av diabetes.
NO20022087D0 (no)	2002-05-02	Fremgangsmåte for behandling av diabetes
ITTO950104A0 (it)	1995-02-15	Catetere, particolarmente per il trattamento di aritmie cardiache.
IT1305566B1 (it)	2001-05-09	Struttura rinforzata, elemento strutturale rinforzato e procedimentoper la loro realizzazione.
SG116501A1 (en)	2005-11-28	Composition for heart disease, method to prepare same and uses thereof.
IS5715A (is)	2001-05-31	Aðferð til smíði á 4-karboxýamínó-2-setnu-1,2,3,4-tetrahýdrókínólíni
TR199801351A3 (tr)	1999-10-21	Yapi elemanlarinin takviyesi için yöntem.
ITTO950099A0 (it)	1995-02-14	Catetere, particolarmente per il trattamento di aritmie cardiache.
IS4975A (is)	1999-08-18	Aðferð til meðhöndlunar á hjartabilun
AU2002258428A1 (en)	2002-09-12	Methods for the treatment of metabolic disorders, including obesity and diabetes
IS7755A (is)	2005-03-17	Aðferð við framleiðslu á (S,S)-cis-2-benshýdríl-3-bensýlamínókínuklídín
MXPA02004119A (es)	2003-10-06	Nuevos ciclopropanos como antagonistas de cgrp, medicamentos que contienen estos compuestos y metodo para obtencion de los mismos.
WO2002072604A3 (en)	2003-12-24	Genes and polymorphisms associated with cardiovascular disease and their use
TR199800608A3 (tr)	1998-10-21	Propanolamin türevleri, bunlarin üretim usulü.
ATE265454T1 (de)	2004-05-15	Phenyloxazol-1,4-diazabicyclo(3.2.2)nonanderiva e,ihre herstellung und ihre therapeutische verwendung
ITMI20002019A0 (it)	2000-09-15	Metodo per il trattemento dei disturbi metabolici, in particolare diabete oppure una malattia oppure una condizione associate con il diabete
ATE251170T1 (de)	2003-10-15	Titanverbindungen, deren herstellung und verwendung
IS7163A (is)	2004-02-26	Aðferðir til meðhöndlunar á lungnasjúkdómi
WO2001072328A3 (en)	2002-02-14	Methods of treating diseases with activated protein c
DE69907898D1 (de)	2003-06-18	Fettreduzierte suessigkeiten enthaltend kombinationen von emulgiermitteln sowie herstellung derselben